KRAS G12V Peptide (TFA)

KRAS G12V Peptide TFA is the trifluoroacetate salt of KRAS G12V Peptide. KRAS G12V Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12V oncogenic mutation. KRAS G12V Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12V Peptide can be used for the study of immune responses against KRAS G12V-mutant tumors[1].

12352209

IFNAR

Immunology/Inflammation

Cancer-programmed cell death

Cancer

97.01

O=C(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(NCC(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@@H](C(C)C)C(NCC(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C(C)C)N.OC(C(F)(F)F)=O.[x]

C40H73N11O11.xC2HF3O2

884.07 (free base)

[1]Zheng W, et al. Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development. Oncol Res. 2024 Nov 13;32 (12) :1837-1850.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P11356A/KRAS-G12V-Peptide-TFA-SDS-MedChemExpress.pdf

Peptides

No Development Reported